LRP1 and neoplasm: This inhibition is actually beneficial for the immune attack against tumor cells (101) Blocking the calreticulin-LRP pathway, even when using anti-CD47 antibodies (which aim to block the “don’t eat me” signal on the surface of tumor cells, making them more susceptible to phagocytosis), impairs the phagocytosis of apoptotic tumor cells and significantly weakens or eliminates the tumor-specific CD8+ T cell immune response.